Business
DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
MINNEAPOLIS, June 24, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming addition as a member of the US small-cap Russell 2000 and Russell 3000 Indexes, effective after the U.S. market closes on June 27.
About this update from Diamedica Therapeutics Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":631,"url":"https://media.zenfs.com/en/business-wire.com/13b0de4d42501b411a21c8c99a16e3cc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Tw37utXVLMozImh8412EnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwMztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/13b0de4d42501b411a21c8c99a16e3cc","width":960,"height":303},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/BgTwOjpv.2gN_lW86JKCRA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/13b0de4d42501b411a21c8c99a16e3cc","width":1200,"height":379}},"lazy":false},{"type":"text","content":"MINNEAPOLIS, June 24, 2025--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming addition as a member of the US small-cap Russell 2000 and Russell 3000 Indexes, effective after the U.S. market closes on June 27.","length":374,"tagName":"p"},{"type":"text","content":"The Russell 3000 Index encompasses the 3,000 largest U.S. companies by market capitalization, representing approximately 98% of the investable U.S. equity market. The Russell 2000 Index is a subset of the Russell 3000, measuring the performance of the small-cap segment. These indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.","length":419,"tagName":"p"},{"type":"text","content":""DiaMedica’s inclusion in the Russell 2000 and Russell 3000 indexes marks an important milestone in our company’s journey," said Rick Pauls, President and CEO of DiaMedica. "This recognition enhances our visibility among the broader investment community, supports increased institutional interest and ownership in our stock and serves as strong validation of our team’s ability drive value for our shareholders."","length":432,"tagName":"p"},{"type":"text","content":"DM199 for Preeclampsia KOL Replay","length":33,"tagName":"p"},{"type":"text","content":"DiaMedica also recently hosted a preeclampsia webinar featuring Prof. Baha Sibai, MD (University of Texas) Prof. Stephen Tong, MD, PhD (The Unive...